TDMS Study 05086-02 Pathology Tables
INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)
O-BENZYL-P-CHLOROPHENOL
NTP Experiment-Test: 05086-02 Report: PEIRPT05
Study Type: CHRONIC Date: 09/11/94
Route: GAVAGE Time: 09:18:14
Facility: Battelle Columbus Laboratory
Chemical CAS #: 120-32-1
Lock Date: None
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 05086-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC O-BENZYL-P-CHLOROPHENOL Date: 09/11/94
Route: GAVAGE Time: 09:18:14
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 120MG/KG 240MG/KG 480MG/KG
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 70 70 70 70
Scheduled Sacrifice 20 20 20 18
Early Deaths
Moribund Sacrifice 9 4 10 12
Natural Death 4 3 5 14
Dosing Accident 3 2 1
Survivors
Terminal Sacrifice 36 40 33 25
Natural Death 1
Animals Examined Microscopically 70 70 70 70
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Gallbladder (67) (47) (48) (63)
Intestine Large, Cecum (70) (50) (51) (70)
Intestine Large, Rectum (67) (50) (50) (70)
Intestine Small, Duodenum (69) (49) (48) (70)
Intestine Small, Ileum (70) (48) (48) (70)
Intestine Small, Jejunum (70) (48) (48) (70)
Liver (70) (50) (50) (70)
Carcinoma, Metastatic, Islets, Pancreatic 1 (2%)
Fibrous Histiocytoma, Metastatic, Ear 1 (2%)
Hepatocellular Carcinoma 2 (3%) 1 (2%) 3 (6%) 2 (3%)
Hepatocellular Carcinoma, Multiple 1 (1%)
Hepatocellular Adenoma 9 (13%) 9 (18%) 11 (22%) 10 (14%)
Hepatocellular Adenoma, Multiple 2 (3%) 5 (10%) 4 (8%) 4 (6%)
Mast Cell Tumor Malignant, Metastatic,
Mesentery 1 (2%)
Mesentery (5) (8) (2)
Hemangioma 1 (13%)
Hemangiosarcoma 1 (13%)
Mast Cell Tumor Malignant 1 (13%)
Pancreas (70) (50) (50) (70)
Salivary Glands (70) (50) (50) (70)
Stomach (70) (51) (50) (70)
Adenocarcinoma 1 (2%)
Stomach, Forestomach (70) (51) (50) (70)
Squamous Cell Papilloma 3 (6%) 2 (4%) 1 (1%)
Stomach, Glandular (70) (51) (50) (70)
____________________________________________________________________________________________________________________________________
Page 2
NTP Experiment-Test: 05086-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC O-BENZYL-P-CHLOROPHENOL Date: 09/11/94
Route: GAVAGE Time: 09:18:14
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 120MG/KG 240MG/KG 480MG/KG
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (69) (50) (49) (70)
Hemangiosarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Gland (70) (50) (50) (70)
Adrenal Gland, Cortex (70) (50) (50) (70)
Islets, Pancreatic (70) (50) (50) (70)
Carcinoma 1 (2%)
Pituitary Gland (67) (50) (47) (67)
Pars Distalis, Adenoma 8 (12%) 4 (8%) 5 (11%) 1 (1%)
Pars Intermedia, Adenoma 1 (2%)
Thyroid Gland (69) (50) (50) (70)
Follicle, Adenoma 1 (1%) 1 (2%) 1 (1%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Ovary (69) (49) (49) (69)
Granulosa Cell Tumor Benign 2 (3%)
Hemangioma 1 (1%)
Hemangiosarcoma 1 (1%)
Teratoma 1 (1%)
Thecoma Benign 1 (1%)
Bilateral, Hemangiosarcoma 1 (2%)
Uterus (70) (52) (56) (70)
Hemangiosarcoma 1 (1%) 1 (2%)
Leiomyoma 1 (1%) 1 (2%) 1 (2%)
Leiomyosarcoma 2 (4%) 1 (1%)
Polyp Stromal 1 (1%) 2 (4%)
Vagina (1) (1)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (70) (50) (50) (70)
Hemangiosarcoma 1 (2%)
Mast Cell Tumor Malignant, Metastatic,
Mesentery 1 (2%)
Lymph Node (69) (50) (48) (70)
Page 3
NTP Experiment-Test: 05086-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC O-BENZYL-P-CHLOROPHENOL Date: 09/11/94
Route: GAVAGE Time: 09:18:14
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 120MG/KG 240MG/KG 480MG/KG
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - cont
Lymph Node, Mandibular (66) (47) (46) (69)
Carcinoma, Metastatic, Islets, Pancreatic 1 (2%)
Fibrous Histiocytoma, Metastatic, Ear 1 (2%)
Lymph Node, Mesenteric (61) (48) (46) (62)
Mast Cell Tumor Malignant, Metastatic,
Mesentery 1 (2%)
Spleen (70) (50) (50) (70)
Hemangiosarcoma 2 (4%) 1 (2%) 1 (1%)
Mast Cell Tumor Malignant, Metastatic,
Mesentery 1 (2%)
Thymus (65) (44) (44) (62)
Thymoma Malignant 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (65) (49) (47) (64)
Skin (70) (50) (50) (69)
Subcutaneous Tissue, Fibrosarcoma 3 (4%) 1 (1%)
Subcutaneous Tissue, Fibrous Histiocytoma 1 (2%)
Subcutaneous Tissue, Hemangioma 1 (1%)
Subcutaneous Tissue, Neurofibrosarcoma 1 (1%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (70) (50) (50) (70)
Hemangiosarcoma 1 (2%)
Skeletal Muscle (2)
Rhabdomyosarcoma 1 (50%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (70) (50) (50) (70)
Meningioma Malignant 1 (2%)
Osteosarcoma, Metastatic, Bone 1 (1%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (69) (50) (50) (70)
Alveolar/Bronchiolar Adenoma 3 (4%) 1 (2%) 4 (6%)
Alveolar/Bronchiolar Carcinoma 2 (3%) 2 (4%) 1 (2%) 1 (1%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%) 2 (3%)
Rhabdomyosarcoma, Metastatic, Skeletal Muscle 1 (1%)
____________________________________________________________________________________________________________________________________
Page 4
NTP Experiment-Test: 05086-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC O-BENZYL-P-CHLOROPHENOL Date: 09/11/94
Route: GAVAGE Time: 09:18:14
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 120MG/KG 240MG/KG 480MG/KG
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Ear (1)
Pinna, Fibrous Histiocytoma 1 (100%)
Harderian Gland (5) (3) (3) (3)
Adenoma 4 (80%) 1 (33%) 2 (67%) 3 (100%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (70) (70) (70) (70)
Urinary Bladder (70) (50) (50) (70)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(70) *(70) *(70) *(70)
Lymphoma Malignant Histiocytic 3 (4%) 4 (6%) 3 (4%)
Lymphoma Malignant Lymphocytic 2 (3%) 1 (1%)
Lymphoma Malignant Mixed 5 (7%) 1 (1%) 3 (4%) 1 (1%)
Lymphoma Malignant Undifferentiated Cell 2 (3%) 4 (6%) 3 (4%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 5
NTP Experiment-Test: 05086-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC O-BENZYL-P-CHLOROPHENOL Date: 09/11/94
Route: GAVAGE Time: 09:18:14
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 MG/KG 120MG/KG 240MG/KG 480MG/KG
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 40 35 29 29
Total Primary Neoplasms 55 52 45 36
Total Animals with Benign Neoplasms 29 25 22 23
Total Benign Neoplasms 34 28 26 25
Total Animals with Malignant Neoplasms 18 16 15 10
Total Malignant Neoplasms 21 24 19 11
Total Animals with Metastatic Neoplasms 1 2 2 3
Total Metastatic Neoplasm 1 6 3 3
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 6
NTP Experiment-Test: 05086-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC O-BENZYL-P-CHLOROPHENOL Date: 09/11/94
Route: GAVAGE Time: 09:18:14
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 120MG/KG 240MG/KG 480MG/KG
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 70 70 70 70
Scheduled Sacrifice 20 20 20 20
Early Deaths
Natural Death 3 3 4 10
Moribund Sacrifice 2 12 6 8
Dosing Accident 2 2
Survivors
Terminal Sacrifice 45 32 38 30
Natural Death 1 1
Moribund Sacrifice 1
Animals Examined Microscopically 70 70 70 70
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Large, Cecum (70) (50) (48) (64)
Leiomyosarcoma 1 (2%)
Intestine Small, Jejunum (69) (51) (48) (65)
Hemangiosarcoma 1 (1%)
Liver (70) (51) (51) (70)
Hemangioma, Multiple 1 (1%)
Hemangiosarcoma 2 (3%) 1 (2%) 1 (1%)
Hemangiosarcoma, Multiple 1 (1%) 1 (1%)
Hepatocellular Carcinoma 7 (10%) 11 (22%) 9 (18%) 5 (7%)
Hepatocellular Carcinoma, Multiple 1 (2%) 2 (4%)
Hepatocellular Adenoma 8 (11%) 13 (25%) 15 (29%) 13 (19%)
Hepatocellular Adenoma, Multiple 13 (19%) 5 (10%) 5 (10%) 2 (3%)
Mesentery (3) (7) (2) (4)
Hemangiosarcoma 1 (25%)
Squamous Cell Carcinoma, Metastatic, Stomach 1 (14%)
Pancreas (70) (51) (49) (70)
Squamous Cell Carcinoma, Metastatic 1 (2%)
Salivary Glands (70) (50) (50) (70)
Hemangioma 1 (1%)
Stomach, Forestomach (70) (53) (51) (70)
Squamous Cell Carcinoma 1 (1%) 1 (2%)
Squamous Cell Papilloma 1 (1%) 2 (4%) 2 (3%)
Stomach, Glandular (70) (52) (51) (70)
Hemangiosarcoma 1 (1%)
Tooth (2) (2)
Adamantinoma Benign 1 (50%)
____________________________________________________________________________________________________________________________________
Page 7
NTP Experiment-Test: 05086-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC O-BENZYL-P-CHLOROPHENOL Date: 09/11/94
Route: GAVAGE Time: 09:18:14
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 120MG/KG 240MG/KG 480MG/KG
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (69) (50) (49) (70)
Hemangiosarcoma 1 (1%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Gland (70) (52) (50) (69)
Capsule, Adenoma 1 (1%) 1 (2%) 4 (8%) 1 (1%)
Adrenal Gland, Cortex (70) (52) (50) (69)
Adenoma 1 (1%) 1 (2%) 1 (1%)
Adrenal Gland, Medulla (69) (52) (49) (68)
Pheochromocytoma Malignant 1 (2%)
Pheochromocytoma Benign 1 (1%)
Thyroid Gland (70) (50) (50) (70)
Follicle, Adenoma 1 (1%) 2 (4%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Prostate (70) (50) (49) (70)
Squamous Cell Carcinoma, Metastatic, Stomach 1 (2%)
Seminal Vesicle (70) (50) (48) (70)
Squamous Cell Carcinoma, Metastatic, Stomach 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (69) (50) (50) (70)
Hemangioma 1 (1%)
Hemangiosarcoma 1 (2%) 1 (1%)
Lymph Node (69) (50) (48) (69)
Squamous Cell Carcinoma, Metastatic, Stomach 1 (2%)
Lumbar, Hemangiosarcoma 1 (1%)
Lymph Node, Mandibular (68) (49) (47) (67)
Carcinoma, Metastatic, Nose 1 (1%)
Lymph Node, Mesenteric (68) (44) (44) (59)
Spleen (70) (50) (49) (70)
Hemangiosarcoma 1 (1%) 2 (4%) 1 (1%)
Thymus (62) (38) (41) (61)
____________________________________________________________________________________________________________________________________
Page 8
NTP Experiment-Test: 05086-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC O-BENZYL-P-CHLOROPHENOL Date: 09/11/94
Route: GAVAGE Time: 09:18:14
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 120MG/KG 240MG/KG 480MG/KG
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (70) (50) (50) (70)
Subcutaneous Tissue, Fibrosarcoma 1 (1%)
Subcutaneous Tissue, Hemangiosarcoma 2 (4%) 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Skeletal Muscle (1)
Squamous Cell Carcinoma, Metastatic 1 (100%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
None
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (70) (52) (50) (70)
Alveolar/Bronchiolar Adenoma 13 (19%) 11 (21%) 5 (10%) 6 (9%)
Alveolar/Bronchiolar Adenoma, Multiple 1 (2%) 1 (2%)
Alveolar/Bronchiolar Carcinoma 1 (1%) 2 (4%) 1 (2%) 1 (1%)
Alveolar/Bronchiolar Carcinoma, Multiple 1 (1%) 1 (2%)
Carcinoma, Metastatic, Nose 1 (1%)
Hepatocellular Carcinoma, Metastatic, Liver 2 (3%) 4 (8%) 2 (4%) 1 (1%)
Mediastinum, Hemangiosarcoma 1 (2%)
Nose (70) (50) (50) (70)
Carcinoma 1 (1%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (3) (4) (4) (3)
Adenoma 3 (100%) 2 (50%) 4 (100%) 2 (67%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (70) (70) (70) (70)
Squamous Cell Carcinoma, Metastatic, Stomach 1 (1%)
Renal Tubule, Adenocarcinoma 2 (3%) 1 (1%)
Page 9
NTP Experiment-Test: 05086-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC O-BENZYL-P-CHLOROPHENOL Date: 09/11/94
Route: GAVAGE Time: 09:18:14
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 120MG/KG 240MG/KG 480MG/KG
____________________________________________________________________________________________________________________________________
URINARY SYSTEM - cont
Renal Tubule, Adenoma 2 (3%) 2 (3%) 2 (3%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(70) *(70) *(70) *(70)
Lymphoma Malignant Mixed 1 (1%) 1 (1%)
Lymphoma Malignant Undifferentiated Cell 1 (1%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 10
NTP Experiment-Test: 05086-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC O-BENZYL-P-CHLOROPHENOL Date: 09/11/94
Route: GAVAGE Time: 09:18:14
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 MG/KG 120MG/KG 240MG/KG 480MG/KG
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 39 36 38 32
Total Primary Neoplasms 63 56 60 47
Total Animals with Benign Neoplasms 31 27 28 28
Total Benign Neoplasms 45 38 38 30
Total Animals with Malignant Neoplasms 17 16 17 11
Total Malignant Neoplasms 18 18 22 17
Total Animals with Metastatic Neoplasms 3 5 2 1
Total Metastatic Neoplasm 4 11 2 1
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 11
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------